查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1927404

慢性骨髓性白血病(CML) 治疗市场按治疗方法、分期、治疗环境和患者年龄组划分 - 全球预测 2026-2032 年

Treating Chronic Myeloid Leukemia by Phase Market by Treatment Type, Phase, Treatment Setting, Patient Age Group - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

慢性骨髓性白血病(CML) 治疗市场按阶段划分，2025 年价值 49.2 亿美元，预计 2026 年将成长至 52.6 亿美元，到 2032 年将达到 80.8 亿美元，复合年增长率为 7.33%。

关键市场统计数据
基准年 2025 49.2亿美元
预计年份：2026年 52.6亿美元
预测年份 2032 80.8亿美元
复合年增长率 (%) 7.33%

临床路径的策略性引入、治疗方法的演变以及相关人员的需求，共同塑造了慢性骨髓性白血病的阶段特异性治疗。

慢性骨髓性白血病) 的临床病程独特，分为三个不同的阶段—慢性期、加速期和急变期—每个阶段都需要量身定制的治疗方案。过去二十年来，治疗的基础已从特异性细胞毒性疗法和异体造血干细胞移植转向分子标靶抑制 BCR-ABL 激酶的药物。这项转变重新定义了治疗目标，从单纯延长存活期转变为实现深度分子缓解、提高生活质量，并在部分患者中实现无治疗缓解。

分子科学的进步、监管的演变以及医疗服务模式的变化如何重新定义慢性骨髓性白血病治疗的临床实践和商业策略

慢性骨髓性白血病）的治疗格局正经历着变革性的转变，这主要得益于分子科学的进步、监管创新以及医疗服务模式的演变。透过一代又一代的蛋白酪氨酸激酶抑制剂精准标靶治疗BCR-ABL融合蛋白，为迭代式药物研发树立了先例，并整体骨髓恶性肿瘤的治疗策略。同时，分子监测技术的改进和标准化的疗效评估标准，使得临床医生能够更早地做出个别化的治疗决策，并考虑对部分患者停止治疗。

评估新的贸易措施和进口成本如何重塑白血病治疗的供应链、临床运作和病患就医途径

美国2025年实施的新关税正在对药品供应链和商业营运产生连锁反应，影响慢性骨髓性白血病治疗药物的可近性、成本结构以及策略采购决策。由于活性药物原料药、製剂和专用生产设备在生产过程中通常需要跨越多个国界，因此增加进口成本的关税将推高药品和原材料的到岸成本，促使製造商重新调整生产基地。为此，一些企业正在加快生产在地化计划，或将供应商多元化，转向受贸易措施影响较小的地区。

关键細項分析揭示了治疗层级、疾病阶段、治疗环境和年龄层如何相互作用，从而决定治疗路径和结果。

细分市场层面的趋势分析揭示了治疗方案、疾病分期、医疗环境和患者年龄如何影响慢性骨髓性白血病的临床决策和服务设计。以治疗方法进行的分析突显了蛋白酪氨酸激酶抑制剂 (TKI) 相对于化疗和造血干细胞移植的重要性，其中第一代药物用于控制疾病，而后续几代药物则用于解决抗药性和耐受性问题。在蛋白酪氨酸激酶抑制剂家族中，第一代药物对于初始疾病控制仍然至关重要，而第二代药物，例如Bosutinib、Dasatinib和尼洛替尼，则常用于治疗耐受性和抗药性，并在特定患者中获得更深层的分子学缓解。第三代药物为具有复杂突变谱或领先治疗后疾病进展的患者提供了标靶治疗选择。

医疗基础设施、法规结构和采购惯例的区域差异如何影响全球治疗方法的普及和患者获取途径。

区域背景对慢性骨髓性白血病新疗法的可近性、治疗模式和应用有着深远的影响。在美洲，先进的门诊基础设施和强大的专科药房网路支援口服标靶治疗的广泛应用，但不同支付方类型以及都市区地区之间仍然存在可及性差异。欧洲市场以及中东和非洲地区的情况也存在显着差异。虽然一些欧洲医疗系统已整合了完善的分子监测和国家治疗通讯协定，以促进符合指南的治疗，但中东和非洲部分地区的基础设施和资源限制了他们获得新一代药物和先进监测能力。在亚太地区，虽然存在高容量治疗中心和快速发展的本地生产能力，但监管路径和报销环境差异很大，导致新药和新兴治疗模式的推广应用曲线各不相同。

策略性企业行动、合作模式和营运重点，旨在推动白血病治疗领域的创新、供应链韧性和患者支援。

领先的药物研发和服务供应商的企业策略将影响慢性骨髓性白血病治疗创新和可及性的方向。製药创新者持续投资于下一代激酶抑制剂，旨在提高对抗药性克隆的疗效，同时降低脱靶毒性并提高患者依从性。药物研发公司、诊断公司和学术机构之间的合作日益普遍，从而能够采用整合的突变来指导治疗方案和简化临床开发流程。受託研究机构(CRO) 和专业临床网路在执行特定阶段的临床试验中发挥关键作用，尤其是在难以招募的加速期和急变期患者中。

为製造商、医疗服务提供者和支付方提供切实可行的建议，以改善治疗效果、保障供应，并使循证医学的产生与基于价值的医疗保健预期相一致。

产业领导者可以采取一系列切实可行的措施来改善慢性骨髓性白血病治疗的临床疗效，确保供应连续性，并加速实现价值交付。首先，投资于整合分子检测、数位化互动和协调个案管理的综合监测和依从性项目，以支持治疗效果的持续发挥，并在临床合理的情况下考虑停止治疗。其次，优先考虑供应链多元化和区域製造伙伴关係，以降低单一来源风险和关税造成的成本波动，同时维持品质和合规性。

调查方法结合了临床证据、监管审查、专家访谈和供应链情境分析，以综合提炼出可操作的循序渐进的见解。

本研究采用多学科调查方法进行综合分析，整合了同侪审查的临床文献、监管指导文件、公共卫生数据、专家访谈和最佳实践，从而全面了解治疗模式及其策略意义。研究重点关注影响疾病各阶段标准治疗决策的随机对照试验、长期观察性研究和指南更新，并对临床证据进行了审查。此外，研究还分析了监管和政策文件，以提取影响商业性和市场准入规划的核准途径、适应症扩展和报销标准的趋势。

整合了相关人员必须整合的临床、营运和政策要求，以改善治疗效果并维持疾病各阶段的医疗服务可近性。

总之，慢性骨髓性白血病治疗已发展成为一个精细化的领域，治疗方法的选择、监测强度和护理环境必须与疾病分期、患者特征和当地基础设施紧密结合。分子标靶治疗和监测技术的进步改变了人们对深度和持久疗效的预期，而商业性和政策趋势也越来越要求可衡量的价值和可靠的真实世界证据。贸易和供应链趋势，包括关税波动，进一步加剧了营运环境的复杂性，并凸显了韧性和策略采购规划的重要性。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8.慢性骨髓性白血病(CML) 治疗市场按分期和治疗方法划分

  • 化疗
  • 干细胞移植
  • 蛋白酪氨酸激酶抑制剂
    • 第一代酪胺酸激酶抑制剂
    • 第二代TKI
      • Bosutinib
      • Dasatinib
      • 尼洛替尼
    • 第三代蛋白酪氨酸激酶抑制剂

9.慢性骨髓性白血病(CML) 治疗市场（依阶段划分）

  • 加速期
  • 爆炸危机
  • 慢性期

第十章慢性骨髓性白血病(CML) 治疗市场依分期及治疗环境划分

  • 住院病人
  • 医院门诊部
  • 专科诊所

第十一章慢性骨髓性白血病(CML) 治疗市场按分期和患者年龄组划分

  • 成人
  • 老年人
  • 儿童

12.慢性骨髓性白血病(CML) 治疗市场按阶段划分：按地区划分

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章慢性骨髓性白血病(CML) 治疗市场按阶段划分：按组别

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14.慢性骨髓性白血病(CML) 治疗市场按阶段划分：按国家/地区划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 美国慢性骨髓性白血病（CML）治疗市场依阶段划分：

第十六章：中国慢性骨髓性白血病（CML）治疗市场分期分析：

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation by Bristol Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy's Laboratories Limited
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Incyte Corporation
  • Intas Pharmaceuticals Limited
  • Janssen Global Services, LLC by Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Limited
  • Viatris Inc.
Product Code: MRR-4F7A6D4FF3A1

The Treating Chronic Myeloid Leukemia by Phase Market was valued at USD 4.92 billion in 2025 and is projected to grow to USD 5.26 billion in 2026, with a CAGR of 7.33%, reaching USD 8.08 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.92 billion
Estimated Year [2026] USD 5.26 billion
Forecast Year [2032] USD 8.08 billion
CAGR (%) 7.33%

A strategic introduction to the clinical pathways, therapeutic evolution, and stakeholder imperatives shaping phase-specific treatment of chronic myeloid leukemia

Chronic myeloid leukemia presents a distinctive clinical pathway characterized by discrete phases-chronic phase, accelerated phase, and blast crisis-each demanding a calibrated therapeutic approach. Over the past two decades, the therapeutic backbone has shifted from non-specific cytotoxic therapies and allogeneic hematopoietic stem cell transplantation toward targeted small molecules that inhibit the BCR-ABL kinase. This evolution reshaped treatment goals from merely extending survival to achieving deep molecular responses, improving quality of life, and enabling treatment-free remission in selected patients.

Clinicians and health system leaders must now navigate a more complex landscape where therapeutic selection depends on prior treatment history, mutational profile, comorbidity burden, and patient preferences. Meanwhile, regulatory frameworks and payer expectations increasingly emphasize real-world evidence and value-based outcomes, prompting manufacturers and providers to align around measurable clinical endpoints. As a result, multidisciplinary decision making-integrating hematology, transplant services, pharmacoeconomics, and patient support programs-has become essential to optimize individual patient journeys and broader service delivery.

Transitioning from historical practice to contemporary standards requires a granular understanding of the drivers of treatment choice across disease phases, the operational implications for treatment settings, and the strategic levers available to stakeholders seeking to improve outcomes while containing costs. This introduction frames the deeper analyses that follow, providing context for the clinical, commercial, and policy trends shaping care for people living with chronic myeloid leukemia.

How molecular advances, regulatory evolution, and care delivery transformation are redefining clinical practice and commercial strategies across chronic myeloid leukemia care

The therapeutic landscape for chronic myeloid leukemia is experiencing transformative shifts driven by advances in molecular science, regulatory innovations, and evolving care delivery models. Precision targeting of the BCR-ABL fusion protein through successive generations of tyrosine kinase inhibitors set a precedent for iterative drug development that now informs strategies across hematologic malignancies. Concurrently, improvements in molecular monitoring techniques and standardized response criteria have enabled clinicians to make earlier, individualized treatment decisions and to consider treatment discontinuation in carefully selected patients.

From a commercial perspective, competition among oral targeted agents has reoriented market dynamics toward differentiated safety profiles, dosing convenience, and long-term tolerability. This has triggered a downstream focus on adherence programs, digital therapeutics, and patient support services that bolster sustained molecular response. At the same time, regulatory agencies are increasingly open to adaptive approval pathways and label expansions based on surrogate markers, encouraging sponsors to generate robust translational and real-world evidence to support broader indications.

Importantly, care delivery is also shifting. Specialty clinics and outpatient infusion centers are expanding their role, enabling more decentralized management of chronic phase disease and reducing reliance on inpatient resources. These shifts create both opportunities and responsibilities for payers, providers, and industry actors to harmonize access strategies, optimize resource allocation, and ensure that innovation translates into measurable improvements in survival and quality of life across diverse patient populations.

Assessment of how new trade measures and import costs are reshaping supply chains, clinical operations, and patient access pathways for leukemia therapies

The imposition of new tariff measures by the United States in two thousand twenty-five has rippled through pharmaceutical supply chains and commercial operations in ways that affect access, cost structures, and strategic sourcing decisions for chronic myeloid leukemia therapies. Active pharmaceutical ingredients, finished dose formulations, and specialized manufacturing equipment often cross multiple borders during production; tariffs that increase import costs can therefore raise the landed cost of drugs and raw materials, prompting manufacturers to reassess production footprints. In response, some sponsors are accelerating plans to localize manufacturing or to diversify suppliers across jurisdictions less affected by trade measures.

Clinical programs and trial operations also feel the impact. Tariffs that increase the cost of investigational products or required devices can influence trial budgeting and site selection, and may complicate multinational supply logistics for phase-specific studies. Moreover, payer negotiations in the United States and in markets closely linked to its trade policy become more complex when baseline cost assumptions shift, which in turn affects formulary placement and patient access programs. Health systems and specialty clinics that manage long-term oral targeted therapies may face higher procurement expenditures, compelling pharmacy and procurement teams to renegotiate contracts and seek alternative sourcing strategies.

Policymakers, regulators, and industry actors are pursuing mitigation tactics. These include expanding bilateral manufacturing agreements, investing in regional API hubs, and leveraging tariff exemption processes where available. In parallel, manufacturers are enhancing transparency around unit costs and total cost of care to strengthen value arguments during reimbursement discussions. Clinicians and health system leaders should anticipate and plan for evolving supply chain contingencies, ensuring that contingency buffers, alternative sourcing pathways, and stakeholder communication plans are in place to preserve continuity of care through each disease phase.

Critical segmentation insights illustrating how therapeutic class, disease phase, treatment setting, and age cohorts interact to determine care pathways and outcomes

Segment-level dynamics reveal how treatment choice, disease phase, care setting, and patient age together shape clinical decision making and service design across chronic myeloid leukemia. Analysis by treatment type underscores the centrality of tyrosine kinase inhibitors relative to chemotherapy and hematopoietic stem cell transplantation, with first generation agents establishing disease control and later generations addressing resistance and tolerability. Within the tyrosine kinase inhibitor family, first generation agents remain important for initial disease control, while second generation agents such as bosutinib, dasatinib, and nilotinib are frequently utilized to manage intolerance or resistance and to achieve deeper molecular responses in selected patients. Third generation agents provide targeted options for complex mutational profiles and for patients who have progressed after earlier lines of therapy.

When viewed by disease phase, chronic phase management emphasizes long-term oral therapy and monitoring to sustain deep molecular responses and consider treatment-free remission strategies, whereas accelerated phase and blast crisis require more aggressive, often combination-based approaches and rapid escalation to transplant where appropriate. Treatment setting further modulates pathways: hospital inpatient units manage acute complications and intensive therapies; hospital outpatient clinics deliver infusions, monitoring, and complex procedural care; and specialty clinics provide longitudinal management for oral targeted therapies alongside adherence and monitoring programs. Patient age groups introduce additional complexity, as pediatric patients require dosing and psychosocial adaptations, geriatric patients present comorbidity and frailty considerations that influence tolerability, and adults represent the largest heterogeneous cohort with varying comorbidity profiles and life-stage priorities.

Together, these segmentation lenses highlight the need for integrated care pathways that align therapeutic choice to disease biology, treatment setting, and patient-specific factors, supporting optimized outcomes across phases of disease progression.

How diverse regional healthcare infrastructures, regulatory frameworks, and procurement practices shape therapy adoption and patient access globally

Regional dynamics exert a profound influence on access, care delivery models, and the adoption of novel therapies for chronic myeloid leukemia. In the Americas, systems with advanced outpatient infrastructures and strong specialty pharmacy networks support broad adoption of oral targeted therapies, yet disparities in access persist across payer types and rural versus urban settings. European markets, the Middle East, and Africa display marked heterogeneity: several European health systems integrate robust molecular monitoring and national treatment protocols that facilitate guideline-concordant care, while parts of the Middle East and Africa face infrastructure and resource constraints that limit access to later-generation agents and advanced monitoring capabilities. The Asia-Pacific region combines high-volume treatment centers and rapidly evolving local manufacturing capacity with significant variability in regulatory pathways and reimbursement environments, contributing to differentiated adoption curves for newer agents and care models.

These geographic distinctions affect everything from the pacing of clinical adoption to supply chain design. Market entrants and established manufacturers must therefore tailor strategies to regional payer expectations, local diagnostic capacity, and distribution channels. Clinics and hospital systems should align molecular monitoring protocols and telehealth-enabled follow-up approaches to regional patient needs, considering the variable availability of hematopoietic stem cell transplantation services and the differing prevalence of comorbid conditions that influence treatment tolerability. Cross-regional collaborations and knowledge sharing can accelerate best practice diffusion, but successful translation requires attention to local regulatory and operational realities.

Strategic corporate behaviors, collaborative models, and operational priorities driving innovation, supply resilience, and patient support in leukemia care

Corporate strategies among leading developers and service providers influence the trajectory of therapeutic innovation and access in chronic myeloid leukemia. Pharmaceutical innovators continue to invest in next-generation kinase inhibitors aiming to improve potency against resistant clones while reducing off-target toxicity and fostering adherence. Partnerships between drug developers, diagnostics firms, and academic centers are increasingly common, enabling integrated approaches to mutation-driven therapy selection and streamlined clinical development. Contract research organizations and specialized clinical networks play a pivotal role in running phase-specific studies, particularly those targeting accelerated phase and blast crisis populations where enrollment is more challenging.

In parallel, manufacturers and health systems are developing comprehensive patient support ecosystems encompassing molecular monitoring, adherence support, and financial navigation to maximize real-world effectiveness of oral targeted therapies. Supply chain resilience has become a strategic priority, prompting investments in geographic diversification of manufacturing and in digital supply chain visibility tools. Additionally, smaller biotech firms and academic spinouts continue to explore complementary modalities, including immunotherapeutic approaches and combination regimens that may alter future standard-of-care algorithms. Collectively, these corporate actions emphasize collaboration across the value chain to address unmet needs, reduce time to diagnosis and appropriate therapy selection, and improve longitudinal outcomes across disease phases.

Actionable recommendations for manufacturers, providers, and payers to enhance outcomes, secure supply, and align evidence generation with value-based care expectations

Industry leaders can take a series of pragmatic actions to strengthen clinical outcomes, secure supply continuity, and accelerate value delivery across chronic myeloid leukemia care. First, invest in integrated monitoring and adherence programs that combine molecular testing, digital engagement, and coordinated case management to support durable responses and enable appropriate consideration of treatment discontinuation where clinically justified. Second, prioritize supply chain diversification and regional manufacturing partnerships that reduce exposure to single-source risks and tariff-driven cost volatility while maintaining quality and regulatory compliance.

Third, align evidence generation with payer needs by embedding pragmatic real-world data collection into post-authorization safety studies and registries, thereby demonstrating value across diverse patient populations and care settings. Fourth, cultivate collaborative research partnerships with academic centers and specialty clinics to accelerate enrollment in phase-specific trials for accelerated phase and blast crisis patients, where unmet need remains highest. Fifth, tailor commercial and access strategies to regional realities, acknowledging differences in diagnostic infrastructure, reimbursement models, and patient support requirements. Finally, engage proactively with policymakers and payers to design value-based contracting models that reflect long-term outcomes and total cost of care, ensuring that innovative therapies deliver measurable benefit while remaining sustainable for healthcare systems.

Methodology that integrates clinical evidence, regulatory review, expert interviews, and supply chain scenario analysis to synthesize actionable, phase-specific insights

This research synthesis relies on a multidisciplinary methodology that integrates peer-reviewed clinical literature, regulatory guidance documents, public health data, expert interviews, and operational best practices to produce a comprehensive view of treatment patterns and strategic implications. Clinical evidence was reviewed with an emphasis on randomized controlled trials, long-term observational studies, and guideline updates that inform standard-of-care decisions across disease phases. Regulatory and policy materials were analyzed to extract trends in approval pathways, label expansions, and reimbursement criteria that alter commercial and access planning.

To contextualize commercial and operational factors, the methodology incorporated structured interviews with hematologists, transplant specialists, specialty pharmacists, and health system procurement leaders, supplementing literature findings with real-world practice insight. Supply chain and tariff impacts were assessed through scenario analysis encompassing cross-border manufacturing flows, procurement contracts, and logistics considerations. Finally, triangulation across data streams ensured that recommendations and insights reflect both empirical evidence and frontline operational experience, producing pragmatic guidance for stakeholders seeking to optimize phase-specific care delivery and strategic planning.

Synthesis of clinical, operational, and policy imperatives that stakeholders must integrate to advance outcomes and sustain access across all phases of disease

In conclusion, the treatment of chronic myeloid leukemia has evolved into a nuanced discipline where therapeutic selection, monitoring intensity, and care setting must be tightly aligned with disease phase, patient characteristics, and regional infrastructure. Advances in molecular targeting and monitoring have transformed expectations around deep and durable responses, while commercial and policy trends increasingly demand measurable value and robust real-world evidence. Trade and supply chain dynamics, including tariff shifts, further complicate the operational landscape and underscore the importance of resilience and strategic sourcing.

Moving forward, stakeholders who succeed will be those that integrate clinical excellence with agile operational strategies: investing in molecular diagnostics and adherence infrastructure, diversifying manufacturing and supply chains, and partnering across the ecosystem to generate the evidence payers require. By adopting these approaches, clinicians, manufacturers, and health systems can improve outcomes across chronic, accelerated, and blast phases of disease, while ensuring that innovation translates into accessible and sustainable care delivery.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Treating Chronic Myeloid Leukemia by Phase Market, by Treatment Type

  • 8.1. Chemotherapy
  • 8.2. Stem Cell Transplantation
  • 8.3. Tyrosine Kinase Inhibitor
    • 8.3.1. First Generation TKI
    • 8.3.2. Second Generation TKI
      • 8.3.2.1. Bosutinib
      • 8.3.2.2. Dasatinib
      • 8.3.2.3. Nilotinib
    • 8.3.3. Third Generation TKI

9. Treating Chronic Myeloid Leukemia by Phase Market, by Phase

  • 9.1. Accelerated Phase
  • 9.2. Blast Crisis
  • 9.3. Chronic Phase

10. Treating Chronic Myeloid Leukemia by Phase Market, by Treatment Setting

  • 10.1. Hospital Inpatient
  • 10.2. Hospital Outpatient
  • 10.3. Specialty Clinic

11. Treating Chronic Myeloid Leukemia by Phase Market, by Patient Age Group

  • 11.1. Adult
  • 11.2. Geriatric
  • 11.3. Pediatric

12. Treating Chronic Myeloid Leukemia by Phase Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Treating Chronic Myeloid Leukemia by Phase Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Treating Chronic Myeloid Leukemia by Phase Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Treating Chronic Myeloid Leukemia by Phase Market

16. China Treating Chronic Myeloid Leukemia by Phase Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. AstraZeneca PLC
  • 17.7. Biogen Inc.
  • 17.8. Bristol-Myers Squibb Company
  • 17.9. Celgene Corporation by Bristol Myers Squibb Company
  • 17.10. Cipla Limited
  • 17.11. Dr. Reddy's Laboratories Limited
  • 17.12. Eisai Co., Ltd.
  • 17.13. F. Hoffmann-La Roche Ltd.
  • 17.14. Gilead Sciences, Inc.
  • 17.15. GlaxoSmithKline PLC
  • 17.16. Incyte Corporation
  • 17.17. Intas Pharmaceuticals Limited
  • 17.18. Janssen Global Services, LLC by Johnson & Johnson Services, Inc.
  • 17.19. Merck KGaA
  • 17.20. Novartis AG
  • 17.21. Pfizer Inc.
  • 17.22. Sun Pharmaceutical Industries Limited
  • 17.23. Takeda Pharmaceutical Company Limited
  • 17.24. Teva Pharmaceutical Industries Limited
  • 17.25. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY FIRST GENERATION TKI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY FIRST GENERATION TKI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY FIRST GENERATION TKI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY BOSUTINIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY BOSUTINIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY BOSUTINIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY DASATINIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY DASATINIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY DASATINIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY NILOTINIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY NILOTINIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY NILOTINIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY THIRD GENERATION TKI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY THIRD GENERATION TKI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY THIRD GENERATION TKI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY ACCELERATED PHASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY ACCELERATED PHASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY ACCELERATED PHASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY BLAST CRISIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY BLAST CRISIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY BLAST CRISIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY CHRONIC PHASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY CHRONIC PHASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY CHRONIC PHASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY HOSPITAL INPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY HOSPITAL INPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY HOSPITAL INPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY HOSPITAL OUTPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY HOSPITAL OUTPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY HOSPITAL OUTPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. ASEAN TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. ASEAN TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GCC TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GCC TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. GCC TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 130. GCC TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2018-2032 (USD MILLION)
  • TABLE 131. GCC TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 132. GCC TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 133. GCC TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. BRICS TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. BRICS TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. G7 TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. G7 TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. G7 TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 151. G7 TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2018-2032 (USD MILLION)
  • TABLE 152. G7 TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 153. G7 TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 154. G7 TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. NATO TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. NATO TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. NATO TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 158. NATO TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2018-2032 (USD MILLION)
  • TABLE 159. NATO TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 160. NATO TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 161. NATO TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED STATES TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. UNITED STATES TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED STATES TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED STATES TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. CHINA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 171. CHINA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. CHINA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2018-2032 (USD MILLION)
  • TABLE 174. CHINA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 175. CHINA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)